Reversal of Hepatic Fibrosis by Human CD34(+) Stem/Progenitor Cell Transplantation in Rats

Area of Science:

• Regenerative Medicine
• Hepatology
• Stem Cell Biology

Background:

• Liver fibrosis is a significant health concern with limited treatment options.
• Human umbilical cord blood (UCB) stem cells offer potential therapeutic benefits due to their accessibility and immunomodulatory properties.

Purpose of the Study:

• To investigate the hepatic potential and therapeutic efficacy of human UCB CD34(+) stem cells in a rat model of liver fibrosis.
• To evaluate the in vitro and in vivo effects of differentiated and undifferentiated UCB stem cells on liver fibrosis.

Main Methods:

• Preparation of a carbon tetrachloride (CCl4)-induced liver fibrosis rat model.
• Isolation and culture of human UCB CD34(+) stem cells using magnetic cell sorting (MACS).
• Administration of UCB stem cells (differentiated and undifferentiated) via intrahepatic (IH) and intravenous (IV) routes in CCl4-treated rats.

Main Results:

• UCB CD34(+) stem cell transplantation led to a significant increase in serum albumin and a significant decrease in serum ALT levels compared to the CCl4 group.
• Histopathological analysis revealed a significant antifibrotic effect of stem cells.
• Gene expression analysis showed decreased collagen gene expression and increased human albumin and MMP2 gene expression in rats treated with UCB stem cells, particularly with undifferentiated cells administered intravenously.

Conclusions:

• Human UCB CD34(+) stem cells possess hepatic potential and can ameliorate liver fibrosis in a rat model.
• Intravenous administration of undifferentiated UCB CD34(+) stem cells demonstrated the most significant therapeutic effects, suggesting a promising cell-based therapy for liver fibrosis.